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by critical evaluation against traditional CEA (Cost Effective Analysis) via a scien-
tific process. Patient and Public Involvement (PPI) in HTA is associated with a low 
evidence base potentially limiting its value. Research presented at ISPOR 2012 by 
the same authors concluded a need to improve and standardize PAG input integra-
tion in HTA decision making. To investigate the way different forms of knowledge / 
experience are used by PAGs in NICE HTA for guideline development and new tech-
nology review. We will look at: 1) Influence of PAG structure, resource capability, 
internal process and the impact of PAG advisory board physician representatives 
on scientific validation of patient input in HTA participation, and 2) Part I results 
will inform further research into selection and ranking criteria of social derived 
data compared with CEA. An iterative PPI best practice approach will be followed. 
Selection criteria: Five UK PAG groups (Neurological, Autoimmune, Rare disease, 
Cardiovascular and Oncology) will be invited to participate. The NICE PPI Unit will 
nominate groups when needed. Inclusion criteria: 1) willingness to participate, 
2) prior involvement in guideline / new technology assessments; and 3) pres-
ence of medical advisory board. Research elements: Application of GRIPP criteria 
(Guidance Reporting Involvement Patient Public) to ensure a strong evidence base 
will guide development of an on-line survey and subsequent focus groups and 
interviews. The survey, designed for SAP review, will study: size of PAG, internal 
process for HTA involvement, previous HTA involvement, data submitted, PAG 
knowledge gaps and involvement of medical advisory board. Follow up by focus 
groups and interviews with PAG and advisory board members to identify insights/ 
themes.
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A crucial component of a systematic review is a clear description of the disposi-
tion of studies throughout the various steps of the review process (de-duplication, 
abstract review, full paper review and final inclusion). This is commonly achieved 
using a PRISMA diagram that shows the number of inclusions and exclusions at 
each stage of the review. This may be supplemented with details of the reasons for 
exclusion. To create the PRISMA diagram it is necessary to keep an on-going count of 
exclusions and inclusions throughout the review process. However, this can pose a 
challenge where the scope of a systematic review changes from the original specifi-
cation. This may happen where the set of licensed treatments or HTA requirements 
vary between jurisdictions or over time. In these cases, it may be time consuming to 
recreate the on-going counts of exclusions that correspond to the modified scope. 
We present a methodology for conducting a modular systematic review in which 
PRISMA diagrams and other descriptions of study disposition can be generated 
corresponding to any subsequent changes of scope. This is achieved by splitting 
the review into a set of ‘component-reviews’ defined by mutually exclusive treat-
ment search terms that comprise the full set of possible intersections between the 
individual treatments. Throughout the systematic review process separate counts of 
abstracts, papers and studies are maintained for each of these component-reviews. 
The results from the component-reviews can then be combined to reflect any final 
review scope (based on individual treatments). We will illustrate the methodology 
with an example review of the comparative efficacy of licenced thiazolidinedione’s 
(TZDs) versus placebo in patients with type 2 diabetes mellitus (T2DM) where there 
are two TZDs licensed in the USA (pioglitazone and rosiglitazone) but only one in 
Europe (pioglitazone).
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Objectives: Systematic reviews are often supplemented with the use of external 
experts to provide guidance on the nuances of the area. This can help add context 
if a review is used to support trial design or health economic model development. 
The ideal expert would have a deep understanding of the area and be well con-
nected to those individuals conducting trials. The aim of the current research 
was to assess whether social network analysis of coauthor networks could be 
used to rapidly and objectively identify individuals with the qualities desired in 
an external expert. MethOds: Publication lists from a recent systematic review 
of rheumatoid arthritis were used to produce a list of links between authors and 
publications. This was then imported into the Gephi program for social network 
analysis. Within Gephi, matrix multiplication was used to transform this net-
work into a coauthorship network. Eigenvector centrality was then used to infer 
the amount of access individual authors have to the research community as a 
whole. The use of eigenvector centrality as a measure of influence within the 
author network was then validated by correlating the centrality scores of a random 
sample of authors against independent ratings of desirability of those individu-
als’ expertise. Results: The coauthor network for rheumatoid arthritis, while 
not completely connected, showed a high degree of connectivity (mean degree: 
26, network diameter: 5). Eigenvector centrality allowed the identification of key 
experts, with the highest scoring experts each providing direct access to approxi-
mately half of the whole network. Eigenvector centrality measures were a reli-
able predictor of mean desirability scores from ten raters (F(1,9)= 20.35, p= 0.0015, 
R-squared= 0.69). cOnclusiOns: Social network analysis of coauthor networks 
provides an efficient and robust method for the identification of expertise, and 
can be used as part of the systematic review process.
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Objectives: Use of economic evaluation of health care technologies is intensively 
discussed in the government in Japan. In order to make evaluation results compa-
rable, standardized method of evaluation is required. We proposed an economic 
evaluation guideline in Japan. MethOds: We organized a research team for devel-
oping guideline. After reviewing guidelines in HTA agencies in the world and cur-
rent debate on issues, we investigated HTA reports and methodology of economic 
evaluation studies in several drugs, devices and procedures. Based on the review of 
these information, the research group discussed and proposed economic evalua-
tion guideline suitable for Japan. Results: Proposed guideline consist of 13 items: 
1) Objective; 2) Perspective of analysis; 3) Comparators; 4) Method of analysis; 
5) Time horizon; 6)Choice of outcomes; 7) Source of clinical data; 8) Costs; 9) 
Productivity loss; 10) Discounting; 11) Modeling; 12) Uncertainty; and 13) Budget 
impact analysis. Guideline sentences are classified into 3 levels, principal, recom-
mended, and optional. cOnclusiOn: This guideline is a proposal by a research 
team. However, it will be needed in the near future for using economic evalua-
tion of health care technologies. Proposed guideline should be tested by adopting 
individual studies.
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Objectives: Bayesian Network Meta-Analysis (NMA) models for binary data 
are well established and special precautions do not usually need to be taken in 
the case of zero cell counts. Furthermore, trials with zero cells in both arms are 
usually excluded from the analysis. However, in sparse networks with only one 
trial per comparison and zero cells in unique link studies, their inclusion may 
be mandatory. Zero frequencies may result in numerical instability and/or large 
variances. The objective of this study was to investigate the effect of different 
methods dealing with zero cells in sparse networks in Bayesian NMA. MethOds: 
A review was conducted to identify methods dealing with zero cells for binary 
outcomes in sparse networks in a Bayesian setting. The identified methods were 
applied to a sparse network with six treatments and one study per comparison. 
The outcome was grade 3+ Adverse Events and measured by Odds Ratio. A fixed 
effects model was fitted with binomial likelihood. The performance of the meth-
ods was assessed by the residual deviance and the Credible Intervals’ (CrI) width 
was compared. Results: We identified three methods: apply a continuity cor-
rection (a constant factor of 0.5 or the reciprocal of the opposite treatment size), 
use of informative priors on treatment effects and placing a distribution on the 
baseline model. We applied all methods and combinations of them. The model 
fit was adequate for all methods (residual deviance [10;12.3] for 12 datapoints). 
The use of different informative priors improved the variability estimates. CrI 
widths were reduced up to 15 times with respect to the original model with vague 
priors. cOnclusiOns: Although the debate on the inclusion of studies with zero 
events in NMA is still open, our research shows that methods are available to 
address this issue. However, no clear recommendations can be provided.
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Observational studies are frequently included in systematic reviews, especially in 
those disease areas where RCTs are limited. While there are very specific tools for 
and guidance on assessing the quality of RCTs, the assessment of observational 
studies is less standardized. OBJECTIVE: To understand and assess the different tools 
used to review the quality of observational studies and to make recommendations 
based on our evaluation. MethOds: First, a systematic review of literature from 
2005-present was conducted in Embase and Medline to determine the frequency 
of use of quality assessment for observational studies and the type of tools used to 
conduct the assessment. Second, we reviewed documentation from NHS guidance 
on quality assessment of non-randomized studies. Finally, we reviewed two years of 
approved HTA submissions to see what methods of assessment have been used for 
submissions. Results: A total of 1429 articles were screened. Compared to a similar 
study on older literature, our review found an increase in the use of quality assess-
ment for observational studies. However, we found that many studies continue to 
devise their own tool or adapt existing tools rather than use a tool in its entirety. 
Downs and Black, MOOSE, and STROBE were the most referenced tools, although 
STROBE was not originally intended for such use. Guidelines centered on “non-ran-
domized” studies were mixed and were not always found to be applicable to obser-
vational studies, but instead mostly to single-armed clinical trials. cOnclusiOns: 
There is still a need for guidance and standardization for observational studies 
assessment for use in systematic literature reviews. Although quality assessment 
of observational studies is still not standardized, there are a few methods becom-
ing more frequent in the literature but are difficult to compare across systematic 
literature reviews because they have often been adapted by each author.
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Patient input in HTA pathways by the appropriate disease Patient Advocacy Group 
(PAG) uses principally humanistic and social studies as an evidence base followed 
